Zentalis Pharmaceuticals, Inc. SEC filings document clinical oncology disclosures, financial results, governance matters and capital actions for the ZNTL public company. Recent Form 8-K filings cover azenosertib program updates, Regulation FD corporate presentations, clinical-trial and scientific-presentation exhibits, and results of operations furnished with business updates.
The company’s proxy materials describe board composition, executive compensation, equity awards and shareholder voting matters. Other event filings also record corporate governance changes and completed common stock repurchase activity, alongside cautionary risk language related to clinical development, regulatory pathways and forward-looking statements.
Zentalis Pharmaceuticals director-affiliated entity The Walters Group purchased 6,459,973 shares of the company’s common stock at $1.20 per share. This transaction on 12/31/2025 increased the entity’s holdings to 13,509,973 shares of Zentalis common stock. The filing identifies The Walters Group as the direct holder of the shares, while William T. Walters and Susan B. Walters may be deemed to share voting and dispositive power through their roles with the entity. Each reporting person disclaims beneficial ownership of the reported shares except to the extent of any pecuniary interest.
Zentalis Pharmaceuticals filed an initial ownership report showing that The Walters Group directly holds 7,050,000 shares of the company’s common stock. Footnotes explain that William T. Walters and Susan B. Walters may be deemed to share voting and dispositive power over these shares through The Walters Group, but each reporting person disclaims beneficial ownership except to the extent of any pecuniary interest.
The filing also notes that Zentalis entered into a Stock Purchase Agreement with Matrix Capital Master Fund, LP to repurchase 7,500,000 shares of its common stock, with the repurchase closing on December 15, 2025. As a result of this repurchase, the reporting persons are deemed to be 10% holders, and this status did not arise from any new acquisition of securities by them.
Zentalis Pharmaceuticals, Inc. (ZNTL) disclosed a large insider sale by entities affiliated with Matrix Capital Management Company, LP and its managing general partner, David E. Goel. On 12/15/2025, the reporting persons sold 7,500,000 shares of Zentalis common stock at $1.33 per share in an open market or private sale transaction coded "S".
After this transaction, they reported 6,459,973 shares of Zentalis common stock beneficially owned on an indirect basis, held through Matrix Capital Management Master Fund, LP. The reporting persons, including the investment manager and Mr. Goel, expressly disclaim beneficial ownership of these securities except to the extent of their pecuniary interest.
Zentalis Pharmaceuticals agreed to repurchase 7,500,000 shares of its common stock from Matrix Capital’s fund at $1.33 per share, below the recent $1.40 closing price. The buyback, which closed on December 15, 2025, is tied to Matrix Capital Management’s previously announced plan to wind down its family of funds.
The company states that this repurchase is not expected to materially affect its projected cash runway into late 2027. On the same date, Karan Takhar, a Matrix executive, resigned from Zentalis’ Board of Directors and all board committees, with the company noting there was no disagreement over operations or policies. Following his departure, the board size was reduced from seven to six directors.
Zentalis Pharmaceuticals (ZNTL) filed its Q3 2025 report, highlighting lower operating spend and a solid cash position while advancing azenosertib in ovarian cancer. The company reported a Q3 net loss of $26.7 million on operating expenses of $33.7 million, driven by R&D $23.0 million and G&A $10.8 million. Investment and other income contributed $7.0 million in the quarter.
Cash, cash equivalents and marketable securities totaled $280.7 million as of September 30, 2025, and management believes this will fund operations into late 2027. Year to date, the company recorded $7.8 million in restructuring charges tied to a roughly 40% workforce reduction. Shares outstanding were 72,250,779 as of November 1, 2025.
Development continues on azenosertib (WEE1 inhibitor) in Cyclin E1‑positive platinum‑resistant ovarian cancer. DENALI Part 2 is enrolling, with topline data anticipated by year end 2026, and a Phase 3 confirmatory study is planned to run concurrently with Part 2b. The company noted that the October 1, 2025 U.S. government shutdown could delay FDA and SEC timelines.
Zentalis Pharmaceuticals (ZNTL) furnished an update via Form 8-K. The company announced its financial results for the quarter ended September 30, 2025, and provided business updates. A press release was furnished as Exhibit 99.1 and a corporate presentation as Exhibit 99.2, both beginning November 10, 2025. The materials under Items 2.02 and 7.01 are furnished, not filed, and are not subject to Section 18 liabilities or automatically incorporated by reference.
Form 3 initial statement: The reporting person, James B. Bucher, identified his relationship to Zentalis Pharmaceuticals, Inc. as a director and Chief Legal Officer and filed an initial Section 16 Form 3. The filing states no securities are beneficially owned by the reporting person and attaches an exhibit noting a power of attorney. The form is an initial disclosure of ownership status rather than a transaction report.
Zentalis Pharmaceuticals, Inc. reported a leadership transition in its legal function. On August 26, 2025, Andrea Paul notified the Board of her intent to resign as Chief Legal Officer and Corporate Secretary, effective September 18, 2025, to join the partnership of a large international law firm. She will remain a non-executive employee through October 1, 2025.
The company and Ms. Paul expect to enter into a release agreement that will provide payment of her 2025 target annual bonus and continued vesting of her equity awards during a transitional services period, after which certain awards will vest in full. In connection with her resignation, Zentalis appointed James B. Bucher as its new Chief Legal Officer and Corporate Secretary, effective September 18, 2025. The company describes Mr. Bucher as a seasoned life sciences legal executive with extensive public company and strategic transaction experience.